Actively Recruiting
LAG3 Expression in Triple Negative Breast Cancer
Led by Samsung Medical Center · Updated on 2024-02-14
128
Participants Needed
1
Research Sites
267 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
CONDITIONS
Official Title
LAG3 Expression in Triple Negative Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Planned neoadjuvant chemotherapy
- Triple negative breast cancer
You will not qualify if you...
- HER2-positive breast cancer
- Hormone receptor positive breast cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ji-Yeon Kim
Seoul, South Korea, 06351
Actively Recruiting
Research Team
J
Ji-Yeon Kim
CONTACT
M
Mee Ryung Hong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here